We understand the challenges involved in living with a long-term health condition. It can take its toll, both physically and mentally.
We also appreciate how the burden of disease can also fall on friends, partners and other family members.
It is understandable that healthcare professionals want to offer the best possible support and advice they can. In fact, research has shown that there is a demand from healthcare professionals for resources that can help them support their patients1.
Support from their doctor can be especially welcome when a patient is starting out on a new treatment, such as a biosimilar.
With all of this in mind, we have worked closely with healthcare professionals in all the relevant therapy areas to create KabiCare – a patient support program that centres around engagement and support.
KabiCare – supporting everyone on their biosimilar journey
KabiCare is an online education resource, created exclusively by Fresenius Kabi. It provides a range of information and tools to support healthcare professionals and their patients who are living with chronic conditions.
Whether a patient is initiating treatment on a biosimilar or switching to a biosimilar, KabiCare is there to support them as they manage the impact of their disease on day-to-day life. The support offered by KabiCare is designed to help patients gain the greatest benefit from their treatment.
The difference KabiCare can make
KabiCare gives patients access to the information they want while also empowering them to confidently discuss their condition with their doctor.
Likewise, KabiCare offers a suite of resources for healthcare professionals who are treating patients on our biosimilars products.
KabiCare also provides additional resources to help with the more emotional aspects of living with a condition. Its in-depth coaching tool is an invaluable aid in guiding patients towards a way of managing their feelings and mindset.
This is especially important, as the emotional toll that life with a chronic condition can take on a patient must never be underestimated. Research has shown that patients who used a support programme had significantly greater improvements in clinical, functional and patient-reported outcomes than those who didn't use a program2.
At the same time, support programs have been shown to improve persistence on a treatment while also helping to reduce costs3.
KabiCare stands apart from other patient support programmes as it is founded on our deep appreciation of life from a patient’s perspective. We understand that there are many small things which can all add up to make life a little easier.
By providing the expert-created tools to navigate these issues, KabiCare can help patients make the most of their treatment.
KabiCare offers patients:
- Information on their particular condition and how it might affect them.
- Advice on taking their medicine - particularly helpful if the patient has to use a delivery device.
- A comprehensive coaching tool to help patients manage stress and deal with unhelpful thoughts. This is based on Cognitive Behaviour Therapy (CBT) techniques.
- Starter Kits with instructions on taking medicines as well as support with other aspects of life, such as travel.
For healthcare professionals, KabiCare provides:
- Information on the medicines their patients are taking, including a summary of product characteristics (SmPC)
- Access to all the information that their patients can access via KabiCare
- Helpful downloads exclusively for healthcare professionals
1. Gibofsky et al. Health and Quality of Life Outcomes (2018) 16:211; 2. Van den Bosch F, Ostor AJK, Wassenberg S, et al. Impact of Participation in the Adalimumab (Humira) Patient Support Program on Rheumatoid Arthritis Treatment Course: Results from the PASSION Study [published correction appears in Rheumatol Ther. 2017 Jun;4(1):97]. Rheumatol Ther. 2017;4(1):85-96. doi:10.1007/s40744-017-0061-7; 3. Rubin, David T et al. “Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.” Journal of managed care & specialty pharmacy vol. 23,8 (2017): 859-867. doi:10.18553/jmcp.2017.16272